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However, 10-15% of patients fail to achieve CR after initial chemotherapy and an additional 10-30% of patients will experience relapse of lymphoma after achieving complete response. [2] [3] [4] Salvage chemotherapy followed by autologous hematopoietic cell transplant (AHCT) is the standard therapeutic strategy for patients who have persistent or relapsed disease after front line therapy. 5 Approximately 50% of patients ultimately relapse after AHCT. While there are no standard treatment approaches for subjects relapsing after AHCT, allogeneic HCT (allo-HCT), and more recently, novel immunotherapeutic agents, such as the CD30-targeting antibody drug immunoconjugate brentuximab vedotin (BV) 6 and the anti-PD1 monoclonal antibody nivolumab, are considered acceptable salvage strategies. 7 There are several reports on the safety of BV before and after AHCT 8, 9 as well as before allo-HCT. 10 On the other hand, there are limited data on the use of nivolumab before or after allo-HCT.
Given this paucity of reports we hereby summarize our experience using nivolumab before or after allo-HCT.
Five subjects were treated; patient characteristics are listed in Table 1 ; transplant characteristics and outcomes are listed in Table 2 . A median of 9.5 (range 4-17) cycles of nivolumab had been administered at the time of this report.
Nivolumab was prescribed in two patients for treatment of disease relapse after allo-HCT. Patient 1 had disease that relapsed 1 year after allo-HCT. Six cycles of nivolumab therapy resulted in a fourth CR without incidence of GvHD. The patient continues in CR 6 months after discontinuation of nivolumab. Patient 2 had nodular lymphocyte predominant Hodgkin lymphoma, who underwent allo-HCT in third remission using a graft obtained from a matched unrelated donor; complicated by steroid-responsive gastrointestinal grade II acute GvHD. After a brief 5-month remission, she developed diffuse hepatic involvement by Hodgkin lymphoma without hepatic GvHD . Her tumor did not respond to four cycles of nivolumab and she died of hepatic failure.
Three patients received nivolumab prior to allo-HSCT. Patient 3 had classic HL, relapsed 5 years after AHCT, refractory to BV and bendamustine. Nivolumab salvage resulted in complete metabolic response after 10 cycles of therapy; he completed a total of 17 cycles. The patient is in remission 8 months after double-umbilical cord blood transplant. No cytokine release syndrome occurred after transplant. Grade II gastrointestinal acute GvHD was managed with corticosteroids with complete resolution of symptoms.
Patient 4 was a 45-year-old man who presented relapse of Hodgkin lymphoma less than 100 days after AHCT. His disease was refractory to lenalidomide and radiation. Nivolumab treatment resulted in CR after six cycles and he proceeded to allo-HCT using a haploidentical donor graft. Infusion of hematopoietic progenitor cells was complicated by cytokine release syndrome, characterized by hypotension, tachycardia and rash, with improvement after parenteral corticosteroids and supportive care. Neutrophil engraftment occurred 19 days after transplant. The patient, however, died of infectious pneumonia 4 months after transplant. Prophylactic antimicrobials included dapsone, voriconazole and acyclovir.
Patient 5 was diagnosed with advanced stage Hodgkin lymphoma during pregnancy. First line therapy was discontinued secondary to bleomycin-induced pulmonary toxicity, managed with long-term corticosteroids. She presented early relapse after first line therapy and salvage with BV led to a CR, after which she underwent AHCT. She had early recurrence that was BV refractory. CR was achieved with nivolumab. She proceeded to a double-umbilical cord transplant after eight cycles of treatment. She presented cytokine release syndrome characterized by hypotension, bronchospasm and acute renal failure after infusion of the umbilical cord units; she had no evidence of infectious causes and the syndrome responded promptly to parenteral corticosteroids. The patient again experienced an inflammatory reaction during engraftment, characterized by diffuse maculopapular rash, pruritus, fever and dyspnea. Symptoms were managed with parenteral corticosteroids (methylprednisolone 1mg/kg) with good response noted within 24 h. She remains in remission 4 months after transplant.
The anti-PD-1 monoclonal antibodies nivolumab and pembrolizumab are active against Hodgkin lymphoma, with most studies showing activity in subjects whose disease was resistant to multiple agents, 8, 11 including BV. 12 In many of these subjects, the only potentially curative treatment strategy is an allo-HCT. The interaction of these drugs with the transplant procedure is likely to become a common issue in the upcoming years. Recently published clinical trials using anti-PD-1 monoclonal antibodies have specifically excluded patients treated using alloHCT. 8, 11, 12 To the best of our knowledge, there are no detailed reports on the outcomes of patients who received PD-1 blocking agents before or after allo-HCT for Hodgkin lymphoma.
Two of the three subjects treated with nivolumab prior to allo-HCT using alternative donor graft sources had cytokine release syndrome at the time of hematopoietic cell infusion and neutrophil engraftment. Symptoms were managed successfully in both cases with a short course of systemic corticosteroids. The cause of this syndrome could be related to the exposure of donor cells to the anti-PD-1 antibody and may correlate to previously described cases of 'steroid responsive febrile syndrome'. The time from the last nivolumab dose to hematopoietic progenitor cell infusion was 36 and 98 days for patients 4 and 5, respectively. Considering that the half-life of nivolumab is 26.7 days, it is likely some residual circulating antibody was present in both patients, although additional immunologic events independent of the presence of the antibody should be considered. The mechanisms and cells involved in these events are not clear. Previous reports indicate that T cells contained within umbilical cord blood grafts express PD-1 at very low levels (~1%), 13 hence it is possible that different cellular populations, such as NK cells, are mediating these inflammatory responses.
The use of PD-1 blocking agents in the allo-HCT setting has raised several questions including the issue of whether GvHD incidence and severity would be heightened.
14 Our case series includes five subjects who received nivolumab therapy before and/or after allo-HCT; only one subject was previously treated with nivolumab (patient 3) and developed gastrointestinal acute GvHD that promptly responded to corticosteroid therapy. Patient 2 had gastrointestinal acute GvHD prior to the initiation of nivolumab and did not exhibit recurrence or exacerbation of her symptoms.
These observations suggest that nivolumab should be considered as a treatment alternative for patients who have relapse of disease after allo-HCT. A longer follow up and larger, prospective studies will be necessary to determine the incidence of acute and chronic GvHD as well as the degree of disease control that can be achieved by using anti-PD-1 monoclonal antibodies in the allo-HCT setting. Abbreviations: ABVD = adriamycin, blemocyin, vinblastine, dacarbazine; AHCT = autologous hematopoietic cell transplant; BV = brentuximab vedotin; cHL = classic Hodgkin lymphoma; F = female; GCD = gemcitabine, cisplatin, dexamethasone; GemOx = gemcitabine, oxaliplatin; ICE = ifosfamide, carboplatin, etoposide; M = male; NLPHL = nodular lymphocyte predominant Hodgkin lymphoma; NS = nodular sclerosis; R = rituximab. Letter to the Editor
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